Literature DB >> 17412970

Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11-mediated immune evasion.

Katrin Besold1, Nadine Frankenberg, Sandra Pepperl-Klindworth, Jürgen Kuball, Matthias Theobald, Gabriele Hahn, Bodo Plachter.   

Abstract

Immune control of human cytomegalovirus (HCMV) infection can be mediated by CD8+ cytolytic T lymphocytes (CTL). Adoptive transfer of antiviral CTL confers protection against HCMV reactivation and disease. The tegument protein pp65 and the immediate-early 1 protein (IE1) are recognized to be major CTL targets, even though during productive infection the viral immunoevasion proteins gpUS2-11 act to suppress major histocompatibility complex (MHC) class I-restricted antigen presentation. Thus it was not clear how infected cells could be labelled with antigenic peptides in the face of immunoevasion. We show here that the immunodominant peptide pp65NLV was presented by MHC class I in cells infected with a gpUS2-11-competent virus. Presentation of pp65NLV was still detectable at 96 h post-infection, although at low levels. Partial suppression of pp65NLV presentation was dependent on the ability of the infecting strain to express gpUS2-11. MHC class I-restricted antigen presentation in HCMV-infected cells (encoding gpUS2-11) exhibited specificity for pp65-derived peptides, as infected fibroblasts did not present the IE1-derived nonapeptide IE1TMY. Remarkably, infected cells could restore pp65NLV peptide presentation after acid removal of MHC class I despite gpUS2-11 expression. This recovery was shown to be dependent on proteasome functionality. In contrast to IE1, pp65 peptides are loaded on MHC class I molecules to be transported to the cell surface at early and late times after infection in the face of gpUS2-11-mediated immunoevasion. pp65 is therefore the first example of an HCMV protein only incompletely subjected to gpUS2-11-mediated immunoevasion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412970     DOI: 10.1099/vir.0.82686-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  Nucleocytoplasmic shuttling and CRM1-dependent MHC class I peptide presentation of human cytomegalovirus pp65.

Authors:  Nadine Frankenberg; Peter Lischka; Sandra Pepperl-Klindworth; Thomas Stamminger; Bodo Plachter
Journal:  Med Microbiol Immunol       Date:  2012-09-11       Impact factor: 3.402

2.  The tegument protein pp65 of human cytomegalovirus acts as an optional scaffold protein that optimizes protein uploading into viral particles.

Authors:  Sabine Reyda; Stefan Tenzer; Pedro Navarro; Wolfgang Gebauer; Michael Saur; Steffi Krauter; Nicole Büscher; Bodo Plachter
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

Review 3.  Diverse immune evasion strategies by human cytomegalovirus.

Authors:  Vanessa Noriega; Veronika Redmann; Thomas Gardner; Domenico Tortorella
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

4.  Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.

Authors:  Patrick J Hanley; Donald R Shaffer; Conrad R Y Cruz; Stephanie Ku; Benjamin Tzou; Hao Liu; Gail Demmler-Harrison; Helen E Heslop; Clio M Rooney; Stephen Gottschalk; Catherine M Bollard
Journal:  Cytotherapy       Date:  2011-05-04       Impact factor: 5.414

5.  Human cytomegalovirus US3 modulates destruction of MHC class I molecules.

Authors:  Vanessa M Noriega; Julia Hesse; Thomas J Gardner; Katrin Besold; Bodo Plachter; Domenico Tortorella
Journal:  Mol Immunol       Date:  2012-04-10       Impact factor: 4.407

6.  Human cytomegalovirus pUL10 interacts with leukocytes and impairs TCR-mediated T-cell activation.

Authors:  Luca Bruno; Mirko Cortese; Giuseppina Monda; Michela Gentile; Stefano Calò; Francesca Schiavetti; Luisanna Zedda; Elena Cattaneo; Diego Piccioli; Mary Schaefer; Eugenio Notomista; Domenico Maione; Andrea Carfì; Marcello Merola; Yasushi Uematsu
Journal:  Immunol Cell Biol       Date:  2016-05-19       Impact factor: 5.126

7.  Human cytomegalovirus pp71 stimulates major histocompatibility complex class i presentation of IE1-derived peptides at immediate early times of infection.

Authors:  Julia Hesse; Sabine Reyda; Stefan Tenzer; Katrin Besold; Nina Reuter; Steffi Krauter; Nicole Büscher; Thomas Stamminger; Bodo Plachter
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

Review 8.  Dynamics of T cell memory in human cytomegalovirus infection.

Authors:  Edward C P Waller; Elizabeth Day; J G Patrick Sissons; Mark R Wills
Journal:  Med Microbiol Immunol       Date:  2008-02-27       Impact factor: 3.402

Review 9.  Recombinant viruses as tools to study human cytomegalovirus immune modulation.

Authors:  Katrin Besold; Bodo Plachter
Journal:  Med Microbiol Immunol       Date:  2008-02-27       Impact factor: 3.402

10.  Expression of the human cytomegalovirus UL11 glycoprotein in viral infection and evaluation of its effect on virus-specific CD8 T cells.

Authors:  Ildar Gabaev; Endrit Elbasani; Stefanie Ameres; Lars Steinbrück; Richard Stanton; Marius Döring; Tihana Lenac Rovis; Ulrich Kalinke; Stipan Jonjic; Andreas Moosmann; Martin Messerle
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.